公司演示-凯发88

english 中文简体中文繁体

english 中文繁体

投资者关系

信息披露

公司治理

股票信息

投资者查询

电邮订阅

公司演示

康宁杰瑞生物制药投资人演示材料 2021-12-29
康宁杰瑞生物制药投资人演示材料 2021-08-30
公司演示材料更新 2021-05-12
aacr poster #1660_kn046(pd-l1/ctla-4双特异性抗体)联合白蛋白结合型紫杉醇治疗转移性三阴乳腺癌患者的初步安全性、耐受性和疗效结果 2021-04-12
2020年度业绩投资人演示材料 2021-03-24
2020世界肺癌大会壁报-kn046用于治疗晚期非小细胞肺癌(nsclc)患者的ⅱ期临床研究数据 2021-02-01
2020世界肺癌大会迷你口头报告-kn046在罕见胸部肿瘤患者中的初步安全性和有效性结果 2021-02-01
公司演示材料更新 2021-01-21
asco-gi poster-kn046联合放化疗治疗复发和转移性食管鳞癌的初步疗效和安全性数据 2021-01-18
2020 jefferies伦敦线上医疗投资峰会演示材料 2020-11-16
sitc 壁报-kn026与kn046联合治疗her2阳性实体瘤患者的安全性、耐受性和抗肿瘤活性初步结果 2020-11-12
第27届citic clsa年度投资峰会演示材料 2020-09-22
2020 interim result investor presentation 2020-08-28
company recent development report - july 2020 2020-07-30
aacr poster #1181 - using translational tumor growth inhibition modeling approach and population pk analysis to predict efficacious doses for kn026, a her2 bispecific antibody 2020-06-22
2020 jefferies virtual healthcare conference 2020-06-02
asco poster #3021 - envafolimab (kn035) in advanced tumors with mismatch-repair deficiency 2020-05-29
asco poster #1041 - preliminary safety, efficacy and pharmacokinetics (pk) results of kn026, a her2-targeted bispecific antibody in patients (pts) with her2-positive metastatic breast cancer 2020-05-29
asco poster #3020 - the preliminary efficacy and safety data of kn046 (bispecific anti-pd-l1/ctla4) in patients failed on prior immune checkpoint inhibitors therapy 2020-05-29
using translational tumor growth inhibition modeling approach and population pk analysis to predict efficacious doses for kn026, a her2 bispecific antibody 2020-05-28
envafolimab (kn035) in advanced tumors with mismatch-repair deficiency 2020-05-28
the preliminary efficacy and safety data of kn046 in patients failed on prior immune checkpoint inhibitors therapy 2020-05-17
preliminary safety, efficacy and pharmacokinetics (pk) results of kn026, a her2 bispecific antibody in patients (pts) with her2-positive metastatic breast cancer 2020-05-17